St. Jude Children's Research Hospital

What it reported doing in 2024

Education and training: as part of its mission, the institution has developed a global initiative (st. Jude global) to improve the survival rates of children with cancer and other catastrophic diseases worldwide. St. Jude global accomplishes this by sharing knowledge, technology and organizational skills, helping to implement new approaches to treat pediatric cancer globally, and developing regional networks committed to eradicating cancer in children. This mission will be achieved by focusing on three overriding goals: (1) to train the clinical workforce that will be required to meet our mission, (2) to develop and strengthen health systems and patient-centered initiatives that encompass the entire continuum of care required for children with cancer and non-malignant hematological (continued on schedule o) diseases, and (3) to advance knowledge in global pediatric oncology and hematology through research to sustain a continuous improvement in the level and quality of care delivered around the globe. These initiatives are spearheaded by st. Jude experts who work closely with healthcare professionals at our partner sites.the global initiative for childhood cancer, launched in 2018 by st. Jude in partnership with who and global collaborators, aims to address disparities in childhood cancer outcomeswhere survival is below 30% in many low and middle income countries compared to over 80% in high income settings. The initiative seeks to raise global survival to at least 60% by 2030 by strengthening countries' ability to deliver quality cancer care and elevating childhood cancer as a national and international health priority. Stakeholders across sectors are working together to improve access, capacity, and coordinated action for children with cancer worldwide.the global platform for access to childhood cancer medicines is a major effort led by st. Jude to ensure lifesaving cancer treatments are available, accessible, affordable, and high quality for children worldwide. Backed by a $200 million st. Jude investment and built in partnership with who, unicef, and paho, the initiative is restructuring the fragmented pediatric cancer medicine market to help achieve global survival goals. Pilot deliveries began in 2025, with additional countries now onboarding as the program scales toward reaching 120,000 children within the next seven years.graduate programs at both the master's and doctoral levels are offered through a wholly owned subsidiary, st. Jude children's research hospital graduate school of biomedical sciences, llc, to educate the next generation of biomedical researchers to probe the molecular basis of disease, develop novel therapies and train medical professionals to advance global health for children with catastrophic diseases.

Financial Efficiency

• Mission deployment rate: 79.4%; rating input score 79
• Program expense ratio: 92.5%; rating input score 93
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 93.3%; rating input score 93; 21st percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Fail
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Pass
  • Conducts site visits: Fail
  • Requires grant agreements: Pass
  • May require repayment: Fail
• Grant itemization coverage: 99.5%; rating input score 99; 40th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 94.6%; rating input score 95; 45th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 14.1%; rating input score 80; 80th percentile among comparable filings
• Total-asset coverage ratio: 6.82; rating input score 88; 88th percentile among comparable filings
• Liabilities to assets ratio: 0.03; rating input score 92; 92nd percentile among comparable filings
• Officer compensation ratio: 0.8%; rating input score 78; 78th percentile among comparable filings

Growth

• Program expense growth: 9% per year; rating input score 100; 69th percentile among comparable filings
• Revenue growth: 8.8% per year; rating input score 100; 72nd percentile among comparable filings
• Asset growth: 10.9% per year; rating input score 100; 74th percentile among comparable filings